Poster
Avapritinib for the Treatment of GIST: Analysis of Efficacy, Safety, and Patient Management Strategies at the Recommended Phase 2 Dose
Author
Cissimol P. Joseph
Condition
GIST
Drug target
KIT and PDGFRA mutant kinases
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-CTOS-2019-Avapritinib-GIST-Analysis-Efficacy-Safety-Patient-Management-Poster-1.pdf
12 organizations
1 product
Product
AvapritinibOrganization
Washington University School of MedicineOrganization
Dana Farber Cancer Institute, Boston, MAOrganization
Asan Medical CentreOrganization
Oregon Health & Science UniversityOrganization
James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical CenterOrganization
Duke Cancer InstituteOrganization
Vall d’ Hebron Institute of OncologyOrganization
Blueprint Medicines